The alpha glucosidase inhibitors market is projected to grow from USD 3.5 billion in 2025 to USD 4.8 billion by 2035, at a CAGR of 3.2%. Acarbose will dominate with a 42.0% market share, while type 2 diabetes mellitus will lead the indication segment with a 81.0% share.